Drug Trial Radar · NCT07122076
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Aug 22, 2025
Primary completion
Aug 21, 2028
Study completion Aug 21, 2028
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
Conditions
- Autoimmune Diseases
Interventions
GT719 InjectionBiological
GT719 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants experiencing dose limiting toxicityTime frame: 28 days
- Incidence of treatment-emergent adverse eventsTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changzheng Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.